OakChart

Genelux Corp

GNLXHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

1.88-0.07 (-3.59%)
2026-11-12 06:15 CET
Market cap
85.06 USD m
Revenue, TTM
0.01 USD m
Net income, TTM
-35.60 USD m
Free cash flow, TTM
-28.68 USD m
EPS diluted, TTM
-0.87
P/E
-
Compare

Price

GNLX against its 20, 50 and 200-day averages
2050200miss
2.002.503.003.50726K1.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GNLXclose 1.8820-day 2.0950-day 2.34200-day 2.661.8852w low

70.0% under the 52-week high of 6.26 on 12 Nov 2025. 52-week low 1.77 on 5 Nov 2026. Last 15 sessions, 32.8% high to low

Volume 0.87× normal · the line is the 50-bar volume average

Profile

GNLX
52-week range, 2% of the way up
1.776.26

Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay on September 4, 2001 and is headquartered in Westlake Village, CA.

Employees26
IPOJan 26, 2023
Beta0.70
ATR, 14d0.18
Rel volume0.87
Short float11.65%
Insider own14.05%
Inst own32.00%

Snapshot

6 groups

Valuation

Index-
Market Cap85.06M
Enterprise Value68.81M
Income-35.60M
Sales0.01M
Book/sh0.36
Cash/sh0.41
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees26
IPOJan 26, 2023

Ratios

P/E-
Forward P/E-
PEG-
P/S8506.28
P/B5.26
P/C4.56
P/FCF-
EV/EBITDA-
EV/Sales6881.28
Quick Ratio2.39
Current Ratio2.39
Debt/Eq0.15
LT Debt/Eq0.13
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.87
EPS next Y-0.75
EPS next Q-0.20
EPS this Y5.23%
EPS next Y7.77%
EPS next 5Y44.13%
EPS past 3/5Y-59.75% -8.40%
Sales past 3/5Y-91.03% -
EPS Y/Y TTM-1.31%
Sales Y/Y TTM0.00%
EPS Q/Q-7.23%
Sales Q/Q-
EarningsAug 13 AMC
EPS/Sales Surpr.-6.76% -

Ownership

Insider Own14.05%
Insider Trans-1.39%
Inst Own32.00%
Inst Trans1.14%
ROA-121.80%
ROE-177.93%
ROIC-195.51%
Gross Margin-5925.00%
Oper. Margin-455275.00%
Profit Margin-444950.00%
SMA20-10.07%
SMA50-19.65%
SMA200-29.33%
Trades-

Technical

Shs Outstand45.10M
Shs Float38.89M
Short Float11.65%
Short Ratio13.49
Short Interest4.53M
52W High6.26 -69.97%
52W Low1.77 6.21%
Volatility9.22% 10.29%
ATR (14)0.18
RSI (14)39.05
Beta0.70
Rel Volume0.87
Avg Volume335.73K
Volume292,960

Performance

Perf Week-4.08%
Perf Month-25.40%
Perf Quarter-28.52%
Perf Half Y-41.07%
Perf YTD-56.88%
Perf Year-68.56%
Perf 3Y-86.63%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price18.83
Prev Close1.95
Price1.88
Change %-3.59%

Analyst ratings

latest 6 of 6
DateActionAnalystRating changeTargetImplied
Oct 21, 2025InitiatedLLake StreetBuy$16+751.1%
Oct 29, 2024InitiatedGGuggenheimBuy$8+325.5%
Aug 28, 2024InitiatedRROTH MKMBuy$10+431.9%
Nov 27, 2023InitiatedHH.C. WainwrightBuy$35+1,761.7%
Sep 12, 2023InitiatedMMaxim GroupBuy$40+2,027.7%
Feb 15, 2023InitiatedTThe Benchmark CompanySpeculative Buy$10+431.9%

Peers

Mkt cap
TickerCompanyMkt cap
ONCYOncolytics Biotech Inc52.48M
CADLCandel Therapeutics Inc705.50M
REPLReplimune Group Inc2.06B
CGONCg Oncology Inc6.49B
CLDICalidi Biotherapeutics Inc2.48M
VSTMVerastem Inc1.15B
STROSutro Biopharma Inc170.12M
TOVXTheriva Biologics Inc7.39M
NVCTNuvectis Pharma Inc722.17M
FHTXFoghorn Therapeutics Inc125.32M

Insider trading

latest 14 of 32
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Cappello JosephChief Technical OfficerNov 03 '26Sale2.046681,363317,812Nov 05 05:20 PM
Zindrick ThomasPresident and CEONov 03 '26Sale2.053,0896,3171,223,338Nov 05 05:20 PM
Yu YongChief Scientific OfficerNov 03 '26Sale2.016681,344258,020Nov 05 05:20 PM
Cappello JosephChief Technical OfficerAug 31 '26Sale2.7410,25728,112318,480Sep 02 07:05 PM
Zindrick ThomasPresident and CEOAug 31 '26Sale2.6734,46391,8991,226,427Sep 02 07:05 PM
Yu YongChief Scientific OfficerAug 31 '26Sale2.759,68326,658258,688Sep 02 07:05 PM
Yu YongChief Scientific OfficerAug 04 '26Sale2.946531,922268,371Aug 04 08:20 PM
Cappello JosephChief Technical OfficerAug 04 '26Sale2.956531,924328,737Aug 04 08:20 PM
Zindrick ThomasPresident and CEOAug 04 '26Sale2.953,0238,9051,260,890Aug 04 08:20 PM
Smither John WDirectorJul 01 '26Sale2.9112,00034,89891,403Jul 02 04:35 PM
JOHN SMITHERDirectorJul 01 '26Proposed Sale2.9112,00034,898Jul 01 06:16 PM
Smalling RalphHead of RegulatoryJun 03 '26Sale2.9319256367,611Jun 04 08:35 PM
Thomas JohnDirectorJun 01 '26Sale2.9810,00029,801472,784Jun 02 08:35 PM
JOHNNY THOMASOfficerJun 01 '26Proposed Sale3.0510,00030,500Jun 01 04:32 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 150
  • Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy (GlobeNewswire)
  • Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates (GlobeNewswire)
  • Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi-Vec in Ovarian Cancer (GlobeNewswire)
  • Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates (GlobeNewswire) +9.89%
  • Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire) -5.51%
  • Genelux Corporation to Participate in Upcoming Conferences (GlobeNewswire)
  • Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners (GlobeNewswire) -5.36%
  • Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -19.76%
  • Genelux Corporation Announces Proposed Public Offering of Common Stock (GlobeNewswire)
  • Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials (GlobeNewswire) -23.52%
  • Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer (GlobeNewswire)
  • Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire) +5.67%
  • Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates (GlobeNewswire) -32.40%
  • Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.210-0.197-0.2100.000.006
2026Q12026-05-07-0.200-0.195-0.2020.000.006
2025Q42026-03-19-0.240-0.218-0.2450.010.006
2025Q32025-11-05-0.210-0.213-0.2100.000.006
2025Q22025-08-07-0.200-0.216-0.1970.000.005
2025Q12025-05-06-0.210-0.243-0.2150.000.004
2024Q42025-03-28-0.250-0.186-0.2590.000.005
2024Q32024-11-14-0.190-0.196-0.1870.000.005
2024Q22024-08-14-0.220-0.208-0.2220.000.004
2024Q12024-05-09-0.290-0.218-0.2920.010.004
2023Q42024-04-01-0.250-0.188-0.2530.000.004
2023Q32023-11-14-0.200-0.177-0.2010.000.003
2023Q22023-08-14-0.230-0.155-0.2250.000.002
2023Q12023-06-08-0.530-0.530-0.4220.170.171
2022Q42023-05-25-0.390--0.1420.00-1
2022Q32023-02-140.230-0.208---

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-0.425-0.280-0.21211.0711.00
2023FY-1.160-1.108-1.1580.170.18
2024FY-0.950-0.878-0.9500.010.00
2025FY-0.860-0.847-0.8600.010.00
2026FY--0.815--0.00
2027FY--0.752--7.85
2028FY--0.150--78.96
2029FY-0.893--182.72
2030FY-1.687--271.7

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-155000.000.000.00
2026Q3S2026-08-274000.000.000.00
2026Q3S2026-08-145000.000.000.00
2026Q3S2026-08-135000.000.000.00
2026Q3S2026-05-085000.000.000.00
2026Q3S2026-03-204000.000.000.00
2026Q3S2025-11-123000.000.000.00
2026Q3S2025-11-113000.000.000.00
2026Q3S2025-11-103000.000.000.00
2026Q3S2025-11-093000.000.000.00
2026Q3S2025-11-083000.000.000.00
2026Q3S2025-11-073000.000.000.00
2026Q3S2025-11-063000.000.000.00
2026Q3S2025-11-051000.000.000.00

Estimate history

EPS, annual-0.493-0.578-0.694-0.212-1.158-0.95-0.865-0.8679
Period2019202020212022202320242025TTM
EPS, quarterly-0.222-0.187-0.259-0.215-0.197-0.21-0.245-0.202-0.211
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00011.0680.170.0080.0080.01
Period2019202020212022202320242025TTM
Sales, quarterly0000000.00800
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual23.61523.61523.61524.55326.78934.72837.70645.103
Period2019202020212022202320242025MRQ
Shares, quarterly34.51334.53834.72837.73337.32637.61337.70644.8445.103
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.010.010.010.1711.070.000.000.00
Cost of Goods Sold Incl. D&A0.480.570.901.020.970.900.660.48
Gross Profit-0.47-0.57-0.90-0.8510.10-0.90-0.66-0.48
Selling, General and Administrative Excl. Other35.9532.6530.8023.3213.1113.7211.7610.39
Research and Development22.6819.8519.0012.779.086.326.237.53
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-36.42-33.21-31.70-24.16-3.01-14.61-12.42-10.87
Interest Expense0.000.000.003.971.411.811.220.76
Unusual Expense0.000.00-0.370.40-0.31-0.050.000.00
Net Income Before Taxes-35.60-32.15-29.87-28.30-4.11-16.38-13.64-11.63
Income Taxes0.000.000.000.001.100.000.000.00
Consolidated Net Income-35.60-32.15-29.87-28.30-5.21-16.38-13.64-11.63
Net Income From Continuing Operations-35.60-32.15-29.87-28.30-5.21-16.38-13.64-11.63
Net Income-35.60-32.15-29.87-28.30-5.21-16.38-13.64-11.63
EPS (Recurring)-0.79-0.86-0.96-1.15-0.22-0.70-0.58-0.49
EPS (Basic, Before Extraordinaries)-0.87-0.86-0.95-1.16-0.21-0.69-0.58-0.49
EPS (Diluted)-0.87-0.86-0.95-1.16-0.21-0.69-0.58-0.49
EBITDA-35.94-32.64-30.79-23.15-2.04-13.72-11.76-10.39
Non-Operating Income (Expense)0.831.071.460.240.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.237.585.741.991.911.665.333.75
Price To Sales Ratio16,915.9820,261.219,277.962,013.26----
Gross Margin-5,925.00-7,075.00-11,187.50-498.8291.25---
Operating Margin-455,275.00-415,175.00-396,200.00-14,214.71-27.22---
Net Margin-444,950.00-401,812.50-373,362.50-16,645.29-47.05---
Shares Outstanding45.1037.7134.7326.7924.5523.6223.6223.62
Market Capitalization85.0685.0681.51373.48373.48---

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.010.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.090.100.150.140.140.140.230.22
Gross Profit-0.09-0.10-0.14-0.14-0.14-0.14-0.23-0.22
Selling, General and Administrative Excl. Other9.559.079.278.057.657.689.526.72
Research and Development6.515.785.654.744.764.706.524.05
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-9.64-9.17-9.41-8.19-7.79-7.82-9.75-6.94
Interest Expense0.000.000.000.000.00--0.00
Unusual Expense0.000.000.000.000.000.00-0.370.00
Net Income Before Taxes-9.47-8.93-9.25-7.95-7.46-7.49-8.98-6.47
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-9.47-8.93-9.25-7.95-7.46-7.49-8.98-6.47
Net Income From Continuing Operations-9.47-8.93-9.25-7.95-7.46-7.49-8.98-6.47
Net Income-9.47-8.93-9.25-7.95-7.46-7.49-8.98-6.47
EPS (Recurring)-0.21-0.20-0.25-0.21-0.20-0.21-0.27-0.19
EPS (Basic, Before Extraordinaries)-0.21-0.20-0.25-0.21-0.20-0.21-0.26-0.19
EPS (Diluted)-0.21-0.20-0.25-0.21-0.20-0.21-0.26-0.19
EBITDA-9.55-9.07-9.26-8.05-7.65-7.68-9.52-6.72
Non-Operating Income (Expense)0.170.240.170.240.340.320.400.47
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.271.391.922.631.481.421.430.00
Price To Sales Ratio16,915.9813,355.6620,549.67---10,244.8010,230.21
Gross Margin---1,750.00-----
Operating Margin---117,650.00-----
Net Margin---115,587.50-----
Shares Outstanding45.1044.8437.7137.6137.3337.7334.7334.54
Market Capitalization85.06108.43165.91158.65108.30101.8781.5181.85

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments14.6030.8923.190.404.5011.350.42
Short Term Receivables0.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets0.540.651.011.501.330.130.13
Total Current Assets15.1331.5524.201.895.8211.480.55
Net Property, Plant & Equipment3.753.083.601.982.212.452.65
Total Investments and Advances0.000.000.000.000.000.000.00
Other Assets0.140.090.091.660.090.080.08
Total Assets19.0334.7227.895.538.1314.013.28
Short Term Debt Incl. Current Port. of LT Debt0.430.330.6516.666.563.894.61
Accounts Payable4.365.573.786.780.000.000.00
Other Current Liabilities1.441.002.128.1915.9310.6010.12
Total Current Liabilities6.226.906.5531.6322.4814.4914.73
Long Term Debt1.261.541.879.6918.7522.1713.37
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.00
Total Liabilities7.488.448.4241.3141.2436.6628.09
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.020.020.020.02
Common Equity11.5426.2719.47-35.80-33.13-22.68-24.83
Total Shareholders Equity11.5426.2719.47-35.78-33.11-22.66-24.81
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity11.5426.2719.47-35.78-33.11-22.66-24.81
Total Liabilities & Stockholders Equity19.0334.7227.895.538.1314.013.28
Book Value Per Share0.310.760.73-1.46-1.40-0.96-1.05
Tangible Book Value Per Share0.310.760.73-1.46-1.40-0.96-1.05
Full-Time Employees2624231514--
Price to Book Ratio5.262.4615.5415.54---
Return on Assets-119.62-95.41-169.32-76.25-147.99-157.82-
Return on Equity-170.00-130.58-----
Return on Invested Capital-251.09-107.39-132.61----
Quick Ratio2.434.573.690.060.260.790.04
Current Ratio2.434.573.690.060.260.790.04

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-35.60-32.15-29.87-28.30-5.21-16.38-13.64-11.63
Depreciation0.480.570.901.020.970.900.660.48
Other Funds (Non Cash)8.437.356.9910.292.364.825.403.85
Funds from Operations-26.68-24.22-21.98-16.99-1.88-10.67-7.59-7.31
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital1.41-1.050.75-3.28-1.694.080.380.08
Cash from Operating Activities-25.28-25.27-21.23-20.27-3.57-6.58-7.21-7.22
Capital Expenditures-3.41-1.10-0.38-1.02-0.050.00-0.02-1.77
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments12.1213.24-7.75-13.700.000.000.000.00
Purchase of Investments-19.66-18.26-29.00-13.700.000.000.000.00
Sale Or Maturity of Investments31.7831.5021.250.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities8.7112.14-8.13-14.72-0.050.00-0.02-1.77
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock19.209.8928.5143.800.120.298.996.38
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock19.209.8928.5143.800.120.298.996.38
Proceedsfrom Stock Options18.969.6627.8239.340.000.148.996.38
Issuance or Reduction of Debt, Net0.000.000.000.210.97-0.569.161.50
Change in Long Term Debt0.000.000.000.000.97-0.569.161.50
Issuance of Long Term Debt0.000.000.000.001.100.9412.061.95
Reduction of Long Term Debt0.000.000.000.00-0.13-1.50-2.90-0.45
Net Financing Active Other Cash Flow0.000.000.000.00-1.570.000.000.00
Other Financing Activities Uses0.000.000.000.00-1.570.000.000.00
Cash from Financing Activities19.209.8928.5144.02-0.48-0.2718.157.89
Net Change in Cash2.64-3.23-0.859.02-4.10-6.8610.93-1.11
Free Cash Flow-28.68-26.37-21.61-21.30-3.62-6.58-7.22-8.99
Preferred Dividends (Cash Flow)-0.000.000.00----
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments18.6726.2114.6020.9127.9735.10
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.470.550.540.641.260.84
Total Current Assets19.1426.7515.1321.5529.2335.95
Net Property, Plant & Equipment6.925.473.753.312.942.97
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.150.140.140.120.070.07
Total Assets26.2032.3719.0324.9932.2538.98
Short Term Debt Incl. Current Port. of LT Debt0.330.320.430.350.340.34
Accounts Payable6.926.094.363.996.036.69
Other Current Liabilities0.750.861.440.790.610.66
Total Current Liabilities8.007.276.225.136.997.69
Long Term Debt2.092.181.261.271.361.45
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities10.099.457.486.408.359.14
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity16.1122.9211.5418.5923.9029.85
Total Shareholders Equity16.1122.9211.5418.5923.9029.85
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity16.1122.9211.5418.5923.9029.85
Total Liabilities & Stockholders Equity26.2032.3719.0324.9932.2538.98
Book Value Per Share0.360.510.310.490.640.79
Tangible Book Value Per Share0.360.510.310.490.640.79
Full-Time Employees--26--24
Price to Book Ratio5.267.908.826.563.633.57
Return on Assets-121.80-94.12-119.62-97.69-78.50-92.71
Return on Equity-177.93-127.28-170.00-123.35-98.72-131.36
Return on Invested Capital-52.02-35.57-72.23-40.03-29.52-23.94
Quick Ratio2.393.682.434.204.184.67
Current Ratio2.393.682.434.204.184.67

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-9.47-8.93-9.25-7.95-7.46-7.49
Depreciation0.090.100.150.140.140.14
Other Funds (Non Cash)2.231.711.892.611.471.39
Funds from Operations-7.15-7.12-7.21-5.20-5.85-5.96
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.711.061.01-1.38-1.210.53
Cash from Operating Activities-6.44-6.06-6.20-6.58-7.06-5.43
Capital Expenditures-1.53-0.92-0.44-0.52-0.12-0.03
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments7.50-7.627.005.24-2.543.54
Purchase of Investments0.00-14.400.00-5.26-10.54-2.46
Sale Or Maturity of Investments7.506.787.0010.508.006.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities5.97-8.546.564.72-2.653.51
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.3918.540.280.000.059.57
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.3918.540.280.000.059.57
Proceedsfrom Stock Options0.3918.520.050.000.059.55
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.3918.540.280.000.059.57
Net Change in Cash-0.093.940.64-1.85-9.667.64
Free Cash Flow-7.98-6.98-6.63-7.09-7.17-5.46

Revenue breakdown

Pharmaceutical Preparations2024: 8.00K 2025: 8.00K
United States2024: 8.00K 2025: 8.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.65%4.5M38.9M354.47K
2026-10-1511.94%4.6M38.9M284.44K
2026-09-3011.22%4.4M38.9M265.09K
2026-09-1510.53%4.1M38.9M269.14K
2026-08-319.72%3.8M38.8M246.59K
2026-08-149.07%3.5M38.8M209.22K
2026-07-318.02%3.1M38.4M174.74K
2026-07-158.10%3.1M38.4M170.98K
2026-06-307.83%3.0M38.4M188.82K
2026-06-158.29%3.2M38.4M186.33K
2026-05-297.83%3.1M40.1M186.62K
2026-05-157.39%3.0M40.1M187.78K
2026-04-307.86%3.1M40.1M192.87K
2026-04-157.56%3.0M39.9M211.88K
2026-03-317.86%3.1M39.9M253.18K
2026-03-137.15%2.9M39.9M230.89K
2026-02-277.44%3.0M39.8M233.92K
2026-02-137.80%3.1M39.8M242.77K
2026-01-308.11%3.2M38.9M272.23K
2026-01-157.86%3.1M38.9M282.52K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.950.2610.0946101.000.727-0.0560.001
call5.000.004.900.0512.6964470.000.689-0.0740.001
call7.500.001.000.0513.9811000.000.674-0.0830.001
put2.500.101.450.908.92428911.00-0.273-0.0550.001
put5.002.103.702.659.4132.000.00-0.311-0.0740.001
put7.503.106.900.0017.5970.000.00-0.326-0.0830.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-04SCHEDULE 13G/ASEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-06-228-KCurrent report2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-01144Filing for proposed sale of securities under Rule 144.SEC
2026-05-124Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-124Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-124Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-124Statement of changes in beneficial ownership of securities2026-05-11SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11009.02K3
2026-100000
2026-090000
2026-0800159.42K6
2026-070034.90K1
2026-060030.36K2
2026-050012.63K4
2026-040000
2026-030043.45K6
2026-020000
2026-010000
2025-120050.78K2
2025-110036.50K4

Institutional holders

Manager% owned
WOODWARD DIVERSIFIED CAPITAL, LLC5.26%
VANGUARD CAPITAL MANAGEMENT LLC3.74%
Bleichroeder LP3.08%
BlackRock, Inc.0.98%
GEODE CAPITAL MANAGEMENT, LLC0.95%
CM Management, LLC0.89%
BANK OF AMERICA CORP /DE/0.73%
VANGUARD FIDUCIARY TRUST CO0.53%
FLPUTNAM INVESTMENT MANAGEMENT CO0.52%
Global Retirement Partners, LLC0.50%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.66%
VANGUARD EXTENDED MARKET INDEX FUND1.04%
Fidelity Extended Market Index Fund0.46%
iShares Micro-Cap ETF0.31%
Fidelity Total Market Index Fund0.15%
Fidelity Series Total Market Index Fund0.14%
Goldman Sachs Absolute Return Tracker Fund0.11%
Schwab Total Stock Market Index Fund0.06%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.04%
1290 VT Micro Cap Portfolio0.02%

OakChart. GNLX. Cached 15 minutes.